Institute of Translational Medicine – Accelerating innovations for healthcare

Accelerating innovations for healthcare

Acting as a central hub for clinical trials acceleration and stratification, and clinical informatics, the ITM brings experts together to rapidly turn medical science into innovative patient and healthcare system applications. It does this by providing a platform for interaction between basic scientists, academic clinicians, clinical informatics, biostatisticians, trial design experts in biomarker development and validation to accelerate the development of drugs and devices.

Birmingham Health Partners

This brand new world-class clinical research facility is a Birmingham Health Partners (BHP) project; bringing together the University of Birmingham, University Hospitals Birmingham NHS Foundation Trust and the Birmingham Women and Children’s NHS Foundation Trust to create a centre for innovation and excellence in health sciences and diseases.

Industry Partnerships

Understanding the requirements of industry partners engaging with academics, clinicians and trials teams across BHP.

Conference Facilities

The ITM is home to excellent conference facilities and meeting rooms avaialable for hire at the heart of Birmingham Medical Quarter

Research Expertise

Facilitating world class translational research across the full circle of patient care

Education and Training

Continuing development to boost knowledge, support project delivery and improve patient care.

Centre for Rare Diseases

The Centre for Rare Diseases (CfRD) has opened its clinics for seeing patients with multisystem rare diseases in an integrated setting where all specialties and support services are brought together. Patients no longer have to travel to different clinics and hospitals to get all the care and expertise that they need. This area is a great example of personalised medicine as patients often have defined genetic and metabolic abnormalities – the ITM uses this as a central concept in stratifying more common diseases by defined molecular markers that enables specific treatment approaches to be targeted to specific patient groups.

Find out how ITM incorporates the approach of the Centre for Rare Diseases (CfRD)